Darrin Miles Biography and Net Worth

Insider of Agios Pharmaceuticals

Mr. Miles joined Agios in 2015 and currently serves as chief commercial officer. He previously served as SVP U.S. commercial and global marketing as well as vice president, oncology program leadership, where he was instrumental in setting the strategy for the IDH portfolio and leading the program team through the development and approval of TIBSOVO®. Prior to joining Agios, he spent 14 years at Genentech, where he held roles of increasing responsibility including marketing, sales management, reimbursement and lifecycle leadership supporting a broad portfolio of brands including Rituxan®, Herceptin®, Tarceva® and Lucentis®. Mr. Miles also led the U.S. launches of next generation anti-HER2 treatments Perjeta® and Kadcyla®. Prior to Genentech, he spent a number of years at ALZA Corporation and SmithKline Beecham (now GSK) in numerous roles including marketing, market analytics and organization development. Mr. Miles holds a B.S. in applied economics with a minor in biological sciences from Cornell University.

How do I contact Darrin Miles?: The corporate mailing address for Mr. Miles and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Darrin Miles' contact information.
Has Darrin Miles been buying or selling shares of Agios Pharmaceuticals?: Darrin Miles has not been actively trading shares of Agios Pharmaceuticals during the last ninety days. Most recently, Darrin Miles sold 500 shares of the business's stock in a transaction on Friday, March 5th. The shares were sold at an average price of $48.58, for a transaction totalling $24,290.00. Learn More on Darrin Miles' trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 76,141 shares worth more than $2,110,887.90. The most recent insider tranaction occured on September, 26th when CFO Cecilia Jones sold 2,542 shares worth more than $124,634.26. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 9/26/2024.

Darrin Miles Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/5/2021	Sell	500	$48.58	$24,290.00
3/1/2021	Sell	2,200	$47.99	$105,578.00

Darrin Miles Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $53.78

$52.74

$55.67

50 Day Range

MA: $46.44

$40.50

$60.46

2 Week Range

Now: $53.78

$20.96

$62.58

Volume

926,067 shs

Average Volume

704,416 shs

Market Capitalization

$3.07 billion

P/E Ratio

4.73

Dividend Yield

N/A

Beta

0.75

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late